Stay updated on ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.

Latest updates to the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page footer was updated to reflect a new ClinicalTrials.gov release/revision number (v3.5.3 instead of v3.5.2).SummaryDifference0.0%

- Check14 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be an internal version update with no visible changes to content or layout.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 with no visible changes to study details or trial information.SummaryDifference0.0%

- Check72 days agoChange DetectedResults posting information was added (Results First Posted 2026-02-17; Results First Submitted 2024-03-25), and the study now includes Exploratory Arm 1 and 2 as well as Arm B (RP2D) with related dosing details.SummaryDifference6%

- Check79 days agoChange DetectedThe revision label on the page updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

Stay in the know with updates to ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.